59747-00-1

Basic information

• Product Name: ethyl 3-((4-bromophenyl)amino)-2-cyanoacrylate
• Synonyms: ethyl 3-((4-bromophenyl)amino)-2-cyanoacrylate
• CAS NO: 59747-00-1
• Molecular Weight: 295.136
• Mol File: 59747-00-1.mol
• Article Data: 5

Chemical Properties

• CAS DataBase Reference: ethyl 3-((4-bromophenyl)amino)-2-cyanoacrylate(CAS DataBase Reference)
• NIST Chemistry Reference: ethyl 3-((4-bromophenyl)amino)-2-cyanoacrylate(59747-00-1)
• EPA Substance Registry System: ethyl 3-((4-bromophenyl)amino)-2-cyanoacrylate(59747-00-1)

Safety Data

• Hazardous Substances Data: 59747-00-1(Hazardous Substances Data)

Upstream product

• 2305-54-6 2-(Anilinomethylen)-2-cyanessigsaeure-ethylester 
• 30881-03-9 N,N'-bis-(4-bromophenyl)formamidine 
• 105-56-6 ethyl 2-cyanoacetate 
• 7726-95-6 bromine 
• 64-19-7 acetic acid 
• 106-40-1 4-bromo-aniline 
• 94-05-3 ethyl (ethoxymethylene)cyanoacetate 

Downstream Products

• 364793-52-2 6-bromo-4-hydroxyquinoline-3-carbonitrile 
• 364793-54-4 6-bromo-4-chloro-3-quinolinecarbonitrile 
• 1314687-82-5 6-bromoquinoline-3-carbonitrile 
• 798545-30-9 6-bromoquinoline-3-carboxylic acid 
• 364793-52-2 6-bromo-4-oxo-1,4-dihydroquinoline-3-carbonitrile 
• 100061-97-0 2,3-dibromo-3-(4-bromo-anilino)-2-cyano-propionic acid ethyl ester 

Relevant articles and documents

Synthesis of Fused Pyrimidinone and Quinolone Derivatives in an Automated High-Temperature and High-Pressure Flow Reactor

Fused pyrimidinone and quinolone derivatives that are of potential interest to pharmaceutical research were synthesized within minutes in up to 96% yield in an automated Phoenix high-temperature and high-pressure continuous flow reactor. Heterocyclic scaffolds that are either hard to synthesize or require multisteps are readily accessible using a common set of reaction conditions. The use of low-boiling solvents along with the high conversions of these reactions allowed for facile workup and isolation. The methods reported herein are highly amenable for fast and efficient heterocycle synthesis as well as compound scale-ups.

COMBINATION OF KINASE INHIBITORS AND USES THEREOF

The present invention provides for a method for treating a disease condition associated with PI3-kinase a and/or a receptor tyrosine kinase (RTK) in a subject. In another aspect, the invention provides for a method for treating a disease condition associated with PI3-kinase α and/or an RTK in a subject. In yet another aspect, a method of inhibiting phosphorylation of Akt (S473) in a cell is set forth.

Esters of the 3-arylamino-2-cyanoacrylic acid

-